Wird geladen...
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death‐Ligand 1 Blockade: A Case Discussion and Review of the Literature
A breakthrough in oncology over the last 5 years, immunotherapy has proved its salutary effects in a wide range of solid tumors. The targeting of the programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) pathway can restore a competent antitumor T‐cell response by addressing key t...
Gespeichert in:
| Veröffentlicht in: | Oncologist |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Inc.
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7216449/ https://ncbi.nlm.nih.gov/pubmed/32091646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0671 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|